Streetbeat News

Analyst Ratings

GPN

Keybanc analyst Josh Beck maintains an Overweight rating on Global Payments (NYSE:GPN) and raises the price target from $125 to $135.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:42 am

OLO

Piper Sandler analyst Clarke Jeffries maintains an Overweight rating on Olo (NYSE:OLO) and raises the price target from $9 to $10.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:42 am

THC

Raymond James analyst John Ransom maintains a Strong Buy rating on Tenet Healthcare (NYSE:THC) and raises the price target from $85 to $95.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:42 am

RYTM

B of A Securities analyst Tazeen Ahmad has upgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) from Neutral to Buy and raised the price target from $22 to $27.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:42 am

FRSH

Piper Sandler analyst Brent Bracelin maintains an Overweight rating on Freshworks (NASDAQ:FRSH) and raises the price target from $22 to $27.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:42 am

CCCS

Piper Sandler analyst Arvind Ramnani maintains a Neutral rating on CCC Intelligent Solutions (NASDAQ:CCCS) and raises the price target from $10 to $11.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:42 am

ZBRA

Needham analyst James Ricchiuti has reiterated a 'Buy' rating on Zebra Technologies (NASDAQ:ZBRA) and maintained a price target of $285.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:42 am

PAYC

Piper Sandler analyst Arvind Ramnani has reiterated an Overweight rating on Paycom Software (NYSE:PAYC) and maintained a price target of $399.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:42 am

AZPN

Piper Sandler analyst Clarke Jeffries maintains a Neutral rating on Aspen Technology (NASDAQ:AZPN) and raises the price target from $175 to $180.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:42 am

RYTM

Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and maintained a price target of $32.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:42 am